Danaher (DHR) Q2 2026 (USD): EPS 1.94 (exp. 1.84), Revenue 6.3bln (exp. 6.11bln)

• Diagnostics Revenue 2.47bln (exp. 2.34bln)
• Life Sciences Revenue 1.88bln (exp. 1.8bln)
• Biotech Revenue 1.92bln (exp. 1.96bln)

• CEO Rainer Blair says Danaher delivered a better-than-expected Q2, with core growth improving versus Q1 and disciplined execution driving high-single-digit adjusted EPS growth, while Life Sciences delivered its strongest quarter in several years and bioprocessing orders grew mid-teens.

• Sees Q3 core revenue growth between 2.0-3.0% Y/Y, and adj. operating profit margin of about 26.5%.
• Raises FY26 guidance; sees FY adj. EPS between USD 8.45-8.60 (exp. 8.45; prev. saw saw 8.35-8.55)

Danaher's Q2 performance exceeded expectations with EPS of 1.94 vs. expected 1.84 and revenue of 6.3 billion vs. 6.11 billion. The CEO's commentary highlights strong growth in Life Sciences and better core performance, which could positively impact sentiment in the biotech and life sciences sectors, while the upgraded FY guidance reinforces confidence in the firm's growth trajectory.